REFERENCES

• López-MuñozF.AlamoC.CuencaE.ShenWW.ClervoyP.RubioG.History of the discovery and clinical introduction of chlorpromazine.Ann Clin Psychiatry.200517311313516433053
   PubMedGoogle Scholar
• HogartyGE.Prevention of relapse in chronic schizophrenic patients.J Clin Psychiatry.199354suppl1823
   PubMedGoogle Scholar
• García-MagallónB.Silva-FernándezL.Andreu-SánchezJL.Update on the use of steroids in rheumatoid arthritis.Reumatol Clin.20139529730223726772
   PubMedGoogle Scholar
• LeuchtS.TardyM.KomossaK.et al.Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.Lancet.201237998312063207122560607
   PubMed Web of Science ®Google Scholar
• HasanA.FalkaiP.WobrockT.LiebermanJ.GlenthojB.GattazWF.ThibautF.MöllerHJ.World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.World J Biol Psychiatry.201213531837822834451
   PubMed Web of Science ®Google Scholar
• TakeuchiH.SuzukiT.UchidaH.WatanabeK.MimuraM.Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms.Schizophr Res.20121342-321922522154594
   PubMed Web of Science ®Google Scholar
• KreyenbuhlJ.BuchananRW.DickersonFB.DixonLB.Schizophrenia patient outcomes research team (port), the schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009.Schizophr Bull.20103619410319955388
   PubMed Web of Science ®Google Scholar
• HasanA.FalkaiP.WobrockT.et al.WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.World J Biol Psychiatry.201314124423216388
   PubMed Web of Science ®Google Scholar
• GoffDC.FalkaiP.FleischhackerWW.et al.The long-term effects of antipsychotic medication on clinical course in schizophrenia.Am J Psychiatry.2017174984084928472900
   PubMed Web of Science ®Google Scholar
• CorrellCU.SolmiM.VeroneseN.et al.Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.World Psychiatry20171616318028498599
   PubMed Web of Science ®Google Scholar
• MurrayRM.QuattroneD.NatesanS.et al.Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?Br J Psychiatry.2016209536136527802977
   PubMed Web of Science ®Google Scholar
• InselT.Former NIMH Director's Blog: Antipsychotics: Taking the Long View. n.d. Retrieved from www.nimh.nih.gov/about/directors/thomas-insel/blog/2013/antipsychotics-taking-the-long-view.shtml.
   Google Scholar
• Alvarez-JimenezM.O'DonoghueB.ThompsonA.et al.Beyond clinical remission in first episode psychosis: thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era.CNS Drugs.201630535736827106296
   PubMed Web of Science ®Google Scholar
• GøtzschePC.YoungAH.CraceJ.Does long term use of psychiatric drugs cause more harm than good?BMJ.2015350h243525985333
   PubMed Web of Science ®Google Scholar
• MorganC.LappinJ.HeslinM.et al.Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study.Psychol Med.201444132713272625066181
   PubMed Web of Science ®Google Scholar
• LeuchtS.DavisJM.Do antipsychotic drugs lose their efficacy for relapse prevention over time?Br J Psychiatry.2017211312712928864750
   PubMed Web of Science ®Google Scholar
• HuiCLM.HonerWG.LeeEHM.et al.Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomized, double-blind trial.Lancet Psychiatry.20185543244229551618
   PubMed Web of Science ®Google Scholar
• BowtellM.RatheeshA.McGorryP.KillackeyE.O'DonoghueB.Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review.Schizophr Res. 2017 pii: S0920-9964(17)30687-4.
   Google Scholar
• GotfredsenDR.WilsRS.HjorthøjC.et al.Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up.Psychol Med.201747122118212928382874
   PubMed Web of Science ®Google Scholar
• HusaAP.RannikkoI.MoilanenJ.et al.Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study.Schizophr Res.20141581-313414125034761
   PubMed Web of Science ®Google Scholar
• TorgalsbøenAK.Sustaining full recovery in schizophrenia after 15 years: does resilience matter?Clin Schizophr Relat Psychoses.20125419320022182456
   PubMedGoogle Scholar
• HarrowM.JobeTH.Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?Schizophr Bull.201339596296523512950
   PubMed Web of Science ®Google Scholar
• MoilanenJM.HaapeaM.JääskeläinenE.et al.Long-term antipsychotic use and its association with outcomes in schizophrenia - the Northern Finland Birth Cohort 1966.Eur Psychiatry.20163671427311102
   PubMed Web of Science ®Google Scholar
• WunderinkL.NieboerRM.WlersmaD.SytemaS.NienhuisFJ.Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.JAMA Psychiatry.201370991392023824214
   PubMed Web of Science ®Google Scholar
• VolavkaJ.VeveraJ.Very long-term outcome of schizophrenia.Int J Clin Pract.201824e13094
   Google Scholar
• WilsRS.GotfredsenDR.HjorthøjC.et al.Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis.Schizophr Res.2017182424828277310
   PubMed Web of Science ®Google Scholar
• MorrisonAP.HuttonP.WardleM.et al.Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial.Psychol Med.20124251049105621914252
   PubMed Web of Science ®Google Scholar
• McGorryP.Alvarez-JimenezM.KillackeyE.Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more.JAMA Psychiatry.201370989890023824206
   PubMed Web of Science ®Google Scholar
• EackSM.NewhillCE.AndersonCM.RotondiAJ.Quality of life for persons living with schizophrenia: more than just symptoms.Psychiatr Rehabil J.200730321922217269273
   PubMed Web of Science ®Google Scholar
• ChouinardG.JonesBD.Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.Am J Psychiatry.1980137116216101522
   PubMed Web of Science ®Google Scholar
• MullerP.SeemanP.Dopaminergic supersensitivity after neuroleptics: time-course and specificity.Psychopharmacology (Berl).197860111132574
   PubMed Web of Science ®Google Scholar
• MoncrieffJ.Antipsychotic maintenance treatment: time to rethink?PLoS Med.2015128e100186126241954
   PubMed Web of Science ®Google Scholar
• ShiovitzTM.WelkeTL.TigelPD.et al.Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal.Schizophr Bull.19962245915958938913
   PubMed Web of Science ®Google Scholar
• TiihonenJ.TanskanenA.TaipaleH.20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia.Am J Psychiatry.2018appiajp201817091001
   Web of Science ®Google Scholar
• HoBC.AndreasenNC.ZiebellS.PiersonR.MagnottaV.Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia.Arch Gen Psychiatry.201168212813721300943
   PubMed Web of Science ®Google Scholar
• Fusar-PoliP.SmieskovaR.KemptonMJ.HoBC.AndreasenNC.BorgwardtS.Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.Neurosci Biobehav Rev.20133781680169123769814
   PubMed Web of Science ®Google Scholar
• HuhtaniskaS.JääskeläinenE.HirvonenN.et al.Long-term antipsychotic use and brain changes in schizophrenia - a systematic review and meta-analysis.Hum Psychopharmacol.2017322
   PubMed Web of Science ®Google Scholar
• AndreasenNC.NopoulosP.MagnottaV.PiersonR.ZiebellS.HoBC.Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia.Biol Psychiatry.201170767267921784414
   PubMed Web of Science ®Google Scholar
• GuoJY.HuhtaniskaS.MiettunenJ.et al.Longitudinal regional brain volume loss in schizophrenia: relationship to antipsychotic medication and change in social function.Schizophr Res.20151681-229730426189075
   PubMed Web of Science ®Google Scholar
• VeijolaJ.GuoJY.MoilanenJS.et al.Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication.PLoS One.201497e10168925036617
   PubMed Web of Science ®Google Scholar
• WeinmannS.ReadJ.AderholdV.Influence of antipsychotics on mortality in schizophrenia: systematic review.Schizophr Res.2009113111119524406
   PubMed Web of Science ®Google Scholar
• LiebermanJA.Metabolic changes associated with antipsychotic use.Prim Care Companion J Clin Psychiatry.20046Suppl 281316001095
   PubMedGoogle Scholar
• RayWA.ChungCP.MurrayKT.HallK.SteinCM.Atypical antipsychotic drugs and the risk of sudden cardiac death.N Engl J Med.2009360322523519144938
   PubMed Web of Science ®Google Scholar
• VermeulenJ.van RooijenG.DoedensP.NumminenE.van TrichtM.de HaanL.Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.Psychol Med.201747132217222828397632
   PubMed Web of Science ®Google Scholar
• LeuchtS.HeresS.HamannJ.KaneJM.Methodological issues in current antipsychotic drug trials.Schizophr Bull.200834227528518234700
   PubMed Web of Science ®Google Scholar
• BebbingtonPE.AngermeyerM.AzorinJM.MarwahaS.MarteauF.ToumiM.Side-effects of antipsychotic medication and health-related quality of life in schizophrenia.Acta Psychiatr Scand Suppl.2009 438222819132963
   PubMedGoogle Scholar
• FeldhausT.FalkeS.von GruchallaL.et al.The impact of self-stigmatization on medication attitude in schizophrenia patients.Psychiatry Res.201826139139929353769
   PubMed Web of Science ®Google Scholar
• MoncrieffJ.Magic bullets for mental disorders: the emergence of the concept of an “antipsychotic” drug.J Hist Neurosci.2013221304623323530
   PubMed Web of Science ®Google Scholar
• GaebelW.RiesbeckM.WölwerW.et al.Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia.Schizophr Res.20141522347848623643327
   PubMedGoogle Scholar
• KirschnerM.AlemanA.KaiserS.Secondary negative symptoms - A review of mechanisms, assessment and treatment.Schizophr Res.2017186293827230288
   PubMed Web of Science ®Google Scholar
• ArtaloytiaJF.ArangoC.LahtiA.et al.Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers.Am J Psychiatry.2006163348849316513871
   PubMed Web of Science ®Google Scholar
• KotovR.FochtmannL.LiK.et al.Declining clinical course of psychotic disorders over the two decades following first hospitalization: evidence from the Suffolk county mental health project.Am J Psychiatry.2017174111064107428774193
   PubMed Web of Science ®Google Scholar
• SzczypińskiJJ.GolaM.Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia?Rev Neurosci. 2018. pii: /j/revneuro.ahead-of-print/revneuro-2017-0091/revneuro-2017-0091.xml. doi: 10.1515/revneuro-2017-0091. [Epub ahead of print].
   Google Scholar
• GraceAA.GomesFV.The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention.Schizophr Bull. 2018 Jan 29.: 10.1093/schbul/sbx199. [Epub ahead of print].
   Google Scholar
• MaiaTV.FrankMJ.An integrative perspective on the role of dopamine in schizophrenia.Biol Psychiatry.2017811526627452791
   PubMed Web of Science ®Google Scholar
• LevineSZ.RabinowitzJ.EngelR.EtschelE.LeuchtS.Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.Schizophr Res.2008981-331832217949948
   PubMed Web of Science ®Google Scholar
• LeuchtS.KaneJM.KisslingW.HamannJ.EtschelE.EngelRR.What does the PANSS mean?Schizophr Res.2005792-323123815982856
   PubMed Web of Science ®Google Scholar
• LeuchtS.KaneJM.KisslingW.HamannJ.EtschelE.EngelR.Clinical implications of Brief Psychiatric Rating Scale scores.Br J Psychiatry.200518736637116199797
   PubMed Web of Science ®Google Scholar
• LeppingP.SambhiRS.WhittingtonR.LaneS.PooleR.Clinical relevance of findings in trials of antipsychotics: systematic review.Br J Psychiatry.2011198534134521525517
   PubMed Web of Science ®Google Scholar
• DavidsonM.KaparaO.GoldbergS.YoffeR.NoyS.WeiserM.A nation-wide study on the percentage of schizophrenia and bipolar disorder patients who earn minimum wage or above.Schizophr Bull.201642244344725796051
   PubMed Web of Science ®Google Scholar
• LallyJ.AjnakinaO.Di FortiM.et al.Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.Psychol Med.201646153231324027605254
   PubMed Web of Science ®Google Scholar
• VanesLD.MouchlianitisE.CollierT.AverbeckBB.ShergillSS.Differential neural reward mechanisms in treatment-responsive and treatment-resistant schizophrenia.Psychol Med.201814110
   Google Scholar
• HowesOD.McCutcheonR.AgidO.et al.Treatment-resistant schizophrenia: treatment response and resistance in psychosis (trrip) working group consensus guidelines on diagnosis and terminology.Am J Psychiatry.2017174321622927919182
   PubMed Web of Science ®Google Scholar
• HarrowM.JobeTH.FaullRN.Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study.Psychol Med.201444143007301625066792
   PubMed Web of Science ®Google Scholar
• De HertM.SermonJ.GeertsP.VansteelandtK.PeuskensJ.DetrauxJ.The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics.CNS Drugs.201529863765826293744
   PubMed Web of Science ®Google Scholar
• GilbertPL.HarrisMJ.McAdamsLA.JesteDV.Neuroleptic withdrawal in schizophrenic patients. A review of the literature.Arch Gen Psychiatry.19955231731887872841
   PubMed Web of Science ®Google Scholar
• LiebermanJA.KoreenAR.ChakosM.et al.Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.J Clin Psychiatry.199657Suppl 959
   PubMed Web of Science ®Google Scholar
• GilbertPL.HarrisMJ.McAdamsLA.JesteDV.Neuroleptic withdrawal in schizophrenic patients. A review of the literature.Arch Gen Psychiatry.19955231731887872841
   PubMed Web of Science ®Google Scholar
• EmsleyR.NuamahI.HoughD.GopalS.Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.Schizophr Res.20121381293422446143
   PubMed Web of Science ®Google Scholar
• HarrowM.JobeTH.Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?Schizophr Bull.201339596296523512950
   PubMed Web of Science ®Google Scholar
• EngelhardtDM.RosenB.FreedmanN.MargolisR.Phenothiazines in prevention of psychiatric hospitalization. IV. Delay or prevention of hospitalization - a reevaluation.Arch Gen Psychiatry.1967161981015333777
   PubMed Web of Science ®Google Scholar
• WilsRS.GotfredsenDR.HjorthøjC.et al.Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis.Schizophr Res.2017182424828277310
   PubMed Web of Science ®Google Scholar
• MoilanenJ.HaapeaM.MiettunenJ.et al.Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication - a 10-year follow-up of the Northern Finland 1966 Birth Cohort study.Eur Psychiatry.2013281535821920710
   PubMed Web of Science ®Google Scholar
• HarrowM.JobeTH.Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multi-follow-up study.J Nerv Ment Dis.2007195540641417502806
   PubMed Web of Science ®Google Scholar
• VolavkaJ.VeveraJ.Very long-term outcome of schizophrenia.Int J Clin Pract.2018e1309429691957
   PubMed Web of Science ®Google Scholar
• WunderinkL.NieboerRM.WiersmaD.SytemaS.NienhuisFJ.Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.JAMA Psychiatry.201370991392023824214
   PubMed Web of Science ®Google Scholar
• EmsleyR.Discontinuing antipsychotic treatment after a first-episode of psychosis: Who, when and how?Schizophr Res. 2017 Nov 9. pii: S09209964(17)30675-8. doi:10. 1016/j.schres.2017.10.047
   Google Scholar
• CzoborP.Van DornRA.CitromeL.KahnRS.FleischhackerWW.VolavkaJ.Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.Eur Neuropsychopharmacol.201 52581158116626004980
   PubMed Web of Science ®Google Scholar
• CzoborP.VolavkaJ.DerksEM.et al.Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial.J Clin Psychopharmacol.201333225826123422388
   PubMed Web of Science ®Google Scholar
• MohamedS.RosenheckR.McEvoyJ.SwartzM.StroupS.LiebermanJA.Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.Schizophr Bull.200935233634618586692
   PubMed Web of Science ®Google Scholar
• XavierRM.VorderstrasseA.KeefeRSE.DunganJR.Genetic correlates of insight in schizophrenia.Schizophr Res.201819529029729054485
   PubMed Web of Science ®Google Scholar
• FreseFJ 3rd.StanleyJ.KressK.Vogel-ScibiliaS.Integrating evidence-based practices and the recovery model.Psychiatr Serv.200152111462146811684741
   PubMed Web of Science ®Google Scholar
• SaadTC.The history of autonomy in medicine from antiquity to principlism.Med Health Care Philos.201821112513728601921
   PubMed Web of Science ®Google Scholar
• MorantN.AzamK.JohnsonS.MoncrieffJ.The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample.J Ment Health.201717
   Web of Science ®Google Scholar
• Bartels-VelthuisAA.VisserE.ArendsJ.et al.Towards a comprehensive routine outcome monitoring program for people with psychotic disorders: The Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS).Schizophr Res. 2018 Jan 26. pii: 50920-9964(18)30036-7. doi: 10.1016/j. schres. 2018.01.016. [Epub ahead of print].
   Google Scholar
• MorrisonAP.HuttonP.ShiersD.TurkingtonD.Antipsychotics: is it time to introduce patient choice?Br J Psychiatry .2012201838422859572
   PubMed Web of Science ®Google Scholar
• VolavkaJ.VeveraJ.Very long-term outcome of schizophrenia,Int J Clin Pract.2018e1309429691957
   PubMed Web of Science ®Google Scholar
• CaveE.Protecting patients from their bad decisions: rebalancing rights, relationships, and risk.Med Law Rev.201725452755328082611
   PubMed Web of Science ®Google Scholar
• TverskyA.KahnemanD.Availability: A heuristic for judging frequency and probability.Cogn Psychol.197352207232
   Web of Science ®Google Scholar
• LeuchtS.Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?World Psychiatry.20181716616729856564
   PubMed Web of Science ®Google Scholar
• SaposnikG.RedelmeierD.RuffCC.ToblerPN.Cognitive biases associated with medical decisions: a systematic review.BMC Med Inform Decis Mak.201616113827809908
   PubMedGoogle Scholar
• SohlerN.AdamsBG.BarnesDM.CohenGH.PrinsSJ.SchwartzS.Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.Am J Orthopsychiatry.201686547748526652608
   PubMed Web of Science ®Google Scholar
• NishikawaT.HayashiT.KogaI.UchidaY.Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study.Psychiatry.2007701687917492913
   PubMed Web of Science ®Google Scholar
• PrataD.MechelliA.KapurS.Clinically meaningful biomarkers for psychosis: a systematic and quantitative review.Neurosci Biobehav Rev.2014451344124877683
   PubMed Web of Science ®Google Scholar
• CassidyCM.NormanR.ManchandaR.SchmitzN.MallaA.Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years.Schizophr Bull.20103651001100819321629
   PubMed Web of Science ®Google Scholar
• DavidsonM.SaoudJ.StanerC.et al.Efficacy and safety of min-101: a 12-week randomized, double-blind, placebo-controlled trial of a new drug in development for the treatment of negative symptoms in schizophrenia.Am J Psychiatry.2017174121195120228750582
   PubMed Web of Science ®Google Scholar
• GarayRP.BourinM.de PailletteE.SamalinL.HamegA.LlorcaPM.Potential serotonergic agents for the treatment of schizophrenia.Expert Opin Investig Drugs.2016252159170
   PubMed Web of Science ®Google Scholar
• VanoverK.DmitrienkoA.GlassS.et al.Lumateperone (ITI-007) for the treatment of schizophrenia: placebo-controlled clinical trials and an open-label safety switching.Schizophr Bull.201844Suppl 1S341
   Google Scholar
• AnandR.ForrestEC.HartmanRD.GrahamSM.FaravelliL.Antipsychotic efficacy of evenamide (NW-3509) is due to modulation of glutamatergic dysregulation.Schizophr Bull.201844Suppl 1S132
   Google Scholar